BLACK WEEKSLiekovky −15 % · kity −10 % · ostatné −5 %s kódomDoprava po Nemecku zadarmo od 200 €

Táto stránka bola preložená automaticky a môže obsahovať chyby. Ste rodený hovoriaci? Radi privítame vašu spätnú väzbu a opravy.Poslať spätnú väzbu

The Peptide Desk The Peptide Desk

Tieto informácie slúžia výhradne na výskumné a vzdelávacie účely. Nejde o lekárske odporúčania. Produkty nie sú schválené na použitie u ľudí. So zdravotnými otázkami sa obráťte na lekára.

Lexikón

Reta + Cagri Blend

Retatrutide and cagrilintide at a fixed 5:1 ratio in one vial: the triple agonist covers the incretin axis, the amylin analog adds a second satiety pathway.

7 min read 15 sources

Reta + Cagri Blend vial with white powder and the black TPD label on a white podium with a glowing ring, next to two large tangled molecule models of blue and white spheres
Components in phase 3 · not approved

Summary

At a glance

Sources checked on 26 Oct 2026

On the blend
0 trials

no trial with retatrutide and cagrilintide together, as of 26 Oct 202613

Retatrutide alone, phase 3
-25.0 %

Body weight in TRIUMPH-1 at 80 weeks, highest study dose (placebo -3.9%)6

Cagrilintide alone, phase 2
-10.8 %

Body weight at 26 weeks, highest level (placebo -3.0%)3

Half-life of Retatrutide
~6 days

Phase 1b study, fits one dose per week8

Phase 3 of the components
18 trials

14 with Retatrutide, 4 with cagrilintide alone or an arm with it12

  • The blend combines two research substances in a fixed 5:1 ratio: Retatrutide (a triple agonist at GLP-1, GIP and glucagon) and cagrilintide (a long-acting amylin analogue).1410
  • There is no study of the blend, neither in the lab nor in humans. All figures here come from studies of the components.13
  • Retatrutide alone lowered body weight in phase 3 (TRIUMPH-1, 80 weeks) by 25.0 percent on average at the highest study dose, cagrilintide alone by up to 10.8 percent after 26 weeks in phase 2.63
  • The idea of incretin plus amylin is well studied with cagrilintide and semaglutide: 20.4 percent after 68 weeks in phase 3 (REDEFINE 1). Whether it works similarly with Retatrutide as the partner is open.54
  • Neither component is approved (as of October 2026). Everything here is the state of research, not a recommendation.1415
Profil

Updated October 2026

Class
Triple agonist

GLP-1 / GIP / glucagon, + amylin analog

Contents
25mg retatrutide + 5mg cagrilintide

30mg per vial

Route
Subcutaneous

once weekly, dosed as total amount in mg

Half-life
Retatrutide around 6 days

cagrilintide around 7 to 8 days

Status
Not approved

no studies on the combination

Form
Lyophilisate

powder, reconstituted with BAC water

Sizes
30 mg

1 size in the shop

Obsah 15 sections
  1. V skratke
  2. What is Reta + Cagri Blend?
  3. How it works
  4. What you need
  5. Reconstitution
  6. Injection
  7. Use and dosing
  8. What the research shows
  9. Stav výskumu
  10. Side effects
  11. Storage
  12. Príbuzné látky
  13. Časté otázky
  14. Pojmy
  15. Zdroje

What is Reta + Cagri Blend?

Reta + Cagri Blend is a fixed combination of two weight-management research compounds in one vial: 25mg retatrutide (LY3437943), a triple agonist at the GLP-1, GIP and glucagon receptors. It is paired with 5mg cagrilintide, a long-acting, lipidated analog of the beta-cell hormone amylin. Together that is 30mg of active compound per vial at a fixed 5:1 ratio.

The principle is the same as with CagriSema, just with a different incretin partner: an incretin agonist and an amylin analog address two different satiety pathways. Retatrutide is by far the more potent part, which is why the blend is built reta-anchored and dosed that way too. Both building blocks have their own lexicon entries with the details of each mechanism.

The vial comes as lyophilised powder that you reconstitute with bacteriostatic water and inject subcutaneously once a week. There are no controlled studies of this exact combination; the evidence comes from the individual compounds and from research on cagrilintide with semaglutide.

This information is for research and educational purposes only. No medical advice.

Comparison

One to four targets

Which receptors each compound targets, as stated in the TPD lexicon. Tap a card to open its entry.

Simplified: more targets do not automatically mean more effect. The blend itself has not been studied. 91410

How it works

Retatrutide activates three receptors at once. Through the GLP-1 receptor it dampens appetite and slows gastric emptying, the GIP component reinforces the metabolic effects. The glucagon component is associated in research with higher energy expenditure and increased fat breakdown in the liver. In the phase 2 trial the higher doses reached up to 24.2 percent weight reduction after 48 weeks (Jastreboff 2023).

Cagrilintide acts elsewhere: amylin is released together with insulin from the beta cells and works via amylin receptors, mainly in the circumventricular organs of the brainstem. There it strengthens satiety after a meal and likewise slows gastric emptying, but through a pathway independent of the incretin receptors. Thanks to its lipidation, cagrilintide stays active long enough for a weekly dose (Lau 2021).

In the blend both signals come together. That is the logic of the incretin-plus-amylin combinations: in the phase 1b trial of cagrilintide plus semaglutide, weight loss after 20 weeks was 17.1 percent versus 9.8 percent with semaglutide alone (Enebo 2021). Whether this carries over to retatrutide as the partner has not been studied. On top of that, the cagri share in the blend is small: at 2.4mg of blend it is 0.4mg of cagrilintide.

Where it acts

Where the components act

Tap a point or a card. Colour = receptor, grey = seen in studies. All from studies of the components, not of the blend.

  1. Brain

    Lower food intake via Retatrutide (animal models)9

    GLP-1GIP
  2. Stomach

    Gastric emptying slowed (effect of amylin)11

    Amylin
  3. Liver

    Liver fat dropped sharply on Retatrutide (substudy)2

    Glucagon
  4. Energy balance

    Energy expenditure increased (Retatrutide, animal models)9

    Glucagon
  5. Heart

    Heart rate rose slightly on Retatrutide, dose-dependent1

    Observed in trials

Targets in the ChEMBL database14

Compound CHEMBL5095485 + CHEMBL4802169: six recorded mechanisms, type of action on each card.

GLP-1 receptor (Retatrutide)
Gene
GLP1R
UniProt
P43220
ChEMBL
CHEMBL1784
Action
Agonist, direct binding
GIP receptor (Retatrutide)
Gene
GIPR
UniProt
P48546
ChEMBL
CHEMBL4383
Action
Agonist, direct binding
Glucagon receptor (Retatrutide)
Gene
GCGR
UniProt
P47871
ChEMBL
CHEMBL1985
Action
Agonist, direct binding
Amylin receptor 1 (cagrilintide)
Gene
CALCR + RAMP1
UniProt
P30988, O60894
ChEMBL
CHEMBL2111189
Action
Agonist, binding shown in structural data
Amylin receptor 3 (cagrilintide)
Gene
CALCR + RAMP3
UniProt
P30988, O60896
ChEMBL
CHEMBL2111190
Action
Agonist, binding shown in structural data
Calcitonin receptor (cagrilintide)
Gene
CALCR
UniProt
P30988
ChEMBL
CHEMBL1832
Action
Agonist, binding shown in structural data
A cluster of glass fat cells on the left, a glass nerve cell on the right, tangled blue molecule models docking onto Y-shaped receptors on both
Two satiety pathways, each shown in studies of one component. Symbolic image.

What you need

The kit is the same as for retatrutide or cagrilintide on their own:

Supplies

5 things, numbered as in the picture

Tick off what you already have. Vial and BAC water are our real shop photos at the same size.

Reta plus Cagri Blend vial and bacteriostatic water at the same size with the black TPD label, next to two U-100 insulin syringes, two alcohol swabs and a sharps container with a blue lid
  1. Blend vial

    The Reta + Cagri Blend vial with the lyophilised powder (30mg, two compounds)

    In the shop
  2. Bacteriostatic water

    Bacteriostatic water for reconstitution, 2 or 3ml per vial

    In the shop
  3. U-100 insulin syringes

    U-100 insulin syringes

  4. Alcohol swabs

    Alcohol swabs for the vial cap and the skin

  5. Sharps container

    A sealable container for used needles

As an Amazon associate we earn from qualifying purchases. Links open Amazon - no extra cost for you.

One vial lasts a long time: around twelve weeks at 2.4mg per week, twice that at 1.2mg. So a clean routine when piercing the stopper pays off, it gets used a lot.

Reconstitution

All figures refer to the total amount of both compounds; the 5:1 ratio stays fixed in every dose. With 3ml of bacteriostatic water on 30mg you get 10mg of blend per ml: 0.6mg is then 6 units on the U-100 syringe, 1.2mg is 12 units, 2.4mg is 24 units. With 2ml the solution is 15mg per ml, 2.4mg is then 16 units and 1.2mg is 8 units.

The peptide calculator works this out for any water volume. 3ml is the more comfortable standard because every step lands on whole units and the solution is less concentrated. 1ml is too coarse for the low steps, 0.6mg would be only 2 units.

Add the water slowly to the vial, then swirl or shake until everything is clearly dissolved, both are fine. The solution is clear to slightly opalescent; if it turns cloudy, gel-like or lumpy, do not use it.

Step by step

Dissolving the powder

Four steps, the same for every vial size.

  1. 1Wipe the cap

    Clean the rubber stopper with an alcohol swab.

  2. 2Add BAC water

    Just add it, it does not matter if it hits the powder directly.

  3. 3Swirl or shake

    Until everything has dissolved, both are fine.

  4. 4Draw up

    With the U-100 insulin syringe.

Less water higher concentration fewer units on the syringe Example: 30 mg + 3 ml = 10 mg/ml

Injection

Inject subcutaneously into the fat layer under the skin, classically the abdomen (keep two finger widths clear around the navel), the front and the inner side of the thigh or the back of the upper arm. Once a week, ideally on the same weekday, so the level stays even.

Injection

Where and at what angle

Pick a spot or switch the angle. Subcutaneous means: into the fat layer, not the muscle.

Rotate the spot each time, never the same one twice in a row.

90°More fat under the skin

Rule of thumb: where there is more fat under the skin, insert straight at 90 degrees. In lean people with little fat, 45 degrees, so the needle stays in the fat layer. Simplified diagram.

  1. Clean the skin with an alcohol swab and let it dry briefly

  2. Lift a small fold of skin

  3. Insert the needle: at 90 degrees where there is more fat under the skin, at 45 degrees in lean people with little fat

  4. Inject, slowly or briskly both work, wait a moment, then withdraw the needle

  5. Put the needle straight into the sharps container

Rotate the injection site from week to week. People who struggle with nausea often inject in the evening so that the peak of nausea falls into sleep.

Use and dosing

Dosing

Dosing, titration and syringe

Loading the dosing information …

  • Getting started and stepping up, drawn as a staircase
  • Units on the U-100 syringe for every step
  • How long one vial lasts

What the research shows

There is no study of the retatrutide plus cagrilintide combination, neither preclinical nor in humans. The evidence comes from three directions. For retatrutide there is the phase 2 trial (Jastreboff 2023): up to 24.2 percent weight reduction after 48 weeks in the highest dose group, plus the phase 2a data in MASLD with a marked reduction of liver fat (Sanyal 2024).

For cagrilintide, the phase 2 trial with 706 participants over 26 weeks showed dose-dependent weight reduction in mono application (Lau 2021). The principle of combining an amylin analog with an incretin is best documented for cagrilintide plus semaglutide: 17.1 versus 9.8 percent after 20 weeks in the phase 1b trial (Enebo 2021) and 20.4 percent on average after 68 weeks in the phase 3 trial REDEFINE 1 (placebo 3.0 percent).

It does not follow that retatrutide plus cagrilintide works the same way. Retatrutide on its own is already stronger than semaglutide. Whether the small cagri share of the blend adds anything on top is an open question. You find the studies with links in the source block below.

Study results

What the trials measured

Interactive: switch tabs, tap points, show or hide arms. Arms are named relative to each other, no dosing advice.

Body weight over 48 weeks, Retatrutide alone1

Mean change in percent, phase 2 trial with 338 participants

0-5%-10%-15%-20%-25% Week 0Week 24Week 48 -2.1%-8.7%-17.1%-22.8%-24.2%

Placebo: Week 0 0.0%, Week 24 -1.6%, Week 48 -2.1%. Retatrutide level 1 (lowest): Week 0 0.0%, Week 24 -7.2%, Week 48 -8.7%. Retatrutide level 2: Week 0 0.0%, Week 24 -12.9%, Week 48 -17.1%. Retatrutide level 3: Week 0 0.0%, Week 24 -17.3%, Week 48 -22.8%. Retatrutide level 4 (highest, 12 mg): Week 0 0.0%, Week 24 -17.5%, Week 48 -24.2%.

Only the time points reported in the abstract are shown (weeks 0, 24 and 48). Levels 2 and 3 each combine two groups with a different starting dose. Trial with Retatrutide alone, not with the blend.

Body weight at the end of the trial, per component63

Mean change in percent, one trial per component alone

Retatrutide, TRIUMPH-16 Obesity without diabetes, phase 3, 80 weeks
Placebo -3.9%
Retatrutide, lowest study dose -17.6%
Retatrutide, middle study dose -23.7%
Retatrutide, highest study dose (12 mg) -25.0%
Cagrilintide, dose finding3 Overweight and obesity, phase 2, 26 weeks
Placebo -3.0%
Cagrilintide alone, highest level -10.8%

Values from the abstracts. The trials differ in population and duration and are not directly comparable. The blend contains five times as much Retatrutide as cagrilintide.

Cagrilintide together with semaglutide45

Mean change in body weight in percent, a different partner than in the blend

Phase 1b, 20 weeks4 All on semaglutide, plus cagrilintide or placebo
Semaglutide alone -9.8%
Cagrilintide plus semaglutide -17.1%
REDEFINE 1, phase 3, 68 weeks5 Overweight or obesity without diabetes
Placebo -3.0%
Cagrilintide plus semaglutide -20.4%

Values from the abstracts. Shown is the combination with semaglutide, not with Retatrutide. Whether the small cagrilintide share in the blend adds anything to Retatrutide has not been studied.

Glass stomach and a yellowish lobule of fat cells, circled together by bright light trails
Studies exist only for the components. Symbolic image.

Research status

Where the research stands

There is no registered trial of the blend. Listed here are the trials of both components with status, participants and results. As of 26 Oct 2026. 12

  1. Preclinical Cell assays and animal models of the components
  2. Phase 1 4 trials on components, 4 completed
  3. Phase 2 4 trials on components, 4 completed
  4. Phase 3 18 trials on components, 5 completed
  5. Approval not yet
21,779 participants in phase 3 Planned figures for running trials Not approved, neither the blend nor any component. ChEMBL lists both Retatrutide and cagrilintide with phase 3 as the highest phase and no approval year.14
Show all 22 phase 2 and 3 trials on a timelineHide timeline 9 completed 13 running 5 with results
Phase 2
Phase 3

Bar: start to primary endpoint (planned for running trials). Green = completed, blue = progress until 26 Oct 2026. Phase 1: 4 trials on safety and pharmacokinetics, not shown as bars.

Side effects

Both components are considered generally well tolerated in the trials. The profile of both is shaped by gastrointestinal effects. In combination two satiety signals add up, which amplifies nausea especially at the start. Slow titration therefore matters even more than with the individual compounds.

  • Gastrointestinal: nausea, fullness, vomiting, diarrhoea or constipation are the most common observations, clearly dependent on how fast the dose is raised.
  • Fluids and nutrients: with food intake strongly reduced, fluid intake often drops too; drink enough and keep an eye on protein.
  • Heart rate: mild increases in heart rate are documented for the glucagon component of retatrutide.
  • Muscle mass and gallbladder: rapid weight loss takes muscle mass with it and can favour gallbladder problems; resistance training and protein counteract that.
  • Fixed ratio: the dose of both components rises and falls together, neither can be reduced on its own.
  • Evidence: no clinical studies exist for the combination. Long-term data are missing for retatrutide.

If the solution turns gel-like or lumpy, do not use the vial. Slight cloudiness on its own is not a reason.

Tolerability

Frequency in studies of the components

Share with the event in two large phase 3 trials of the components. There are no data on the blend.

8 of 100 Placebo
14 of 100 Retatrutide, lowest study dose
21 of 100 Retatrutide, middle study dose
28 of 100 Retatrutide, highest study dose (12 mg)
Event PlaceboRetatrutide, lowest study doseRetatrutide, middle study doseRetatrutide, highest study dose (12 mg)
Nausea (Retatrutide, TRIUMPH-2)7 8%14%21%28%
Diarrhoea (Retatrutide, TRIUMPH-2)7 13%27%34%34%
Gastrointestinal overall (cagrilintide plus semaglutide, REDEFINE 1)5 40%0%0%0%

Rounded values from the abstracts. TRIUMPH-2: obesity with type 2 diabetes over 80 weeks, REDEFINE 1: overweight without diabetes over 68 weeks. In REDEFINE 1 the complaints were mostly transient and mild to moderate.75

Storage

The unreconstituted powder is robust: normal room temperature (around 20 to 25 degrees) is fine, ideally dark and dry. For longer periods it can go in the fridge, but it does not have to.

Once mixed, it keeps for at least 4 to 6 months in the fridge (2 to 8 °C); the bacteriostatic water brings a preservative for that. At 2.4mg per week a 30mg vial is empty after around twelve weeks. The solution stays perfectly usable for that long. Do not freeze and do not leave it in the sun.

Swirling or shaking is both fine. Going through the same stopper repeatedly is normal, just wipe the cap each time first.

Shelf life

How long it keeps

Undissolved (powder) Room temperature, around 20 to 25 degrees, dark and dry

Robust, no fridge needed. Keeps for several months without trouble.

Dissolved (mixed) Fridge, 2 to 8 degrees, do not freeze

Keeps for at least 4 to 6 months. The bacteriostatic water brings a preservative.

  • Keep it dark
  • Dissolved: 2 to 8 degrees
  • Note the mixing date on the vial
Nine vials with white powder and blue caps in the door shelf of a bright fridge
Powder dark and dry at room temperature, once dissolved into the fridge (2 to 8 degrees), stable there for at least 4 to 6 months. Symbolic image.

Related

Related compounds

Same receptors or blends with Reta + Cagri Blend: all in the TPD lexicon.

FAQ

Common questions about Reta + Cagri Blend

Short answers, each backed by the sources below.

Is the Reta + Cagri Blend approved or studied?

No. As of 26 October 2026 the registry ClinicalTrials.gov lists no trial with Retatrutide and cagrilintide together. Both components are in phase 3 and not approved.131415

Why Retatrutide and cagrilintide together?

Both act on different satiety pathways: Retatrutide on GLP-1, GIP and glucagon, cagrilintide on amylin receptors. With semaglutide as the partner, weight loss in a phase 1b trial after 20 weeks was 17.1 instead of 9.8 percent. For Retatrutide as the partner there are no data.9104

What do the studies of the components show?

Retatrutide alone: in TRIUMPH-1 after 80 weeks 25.0 percent less body weight on average at the highest study dose, 3.9 percent on placebo. Cagrilintide alone: up to 10.8 percent after 26 weeks in phase 2, 3.0 percent on placebo. In a substudy liver fat also fell sharply on Retatrutide.632

Why is the cagrilintide share so small?

The vial contains five times as much Retatrutide as cagrilintide, because Retatrutide is the stronger and limiting part. Anyone going by the Retatrutide share stays far below the amounts used in the cagrilintide trials. Whether the small share contributes anything has not been studied.313

How long do the components stay in the body?

Retatrutide had a half-life of about six days in a phase 1b study, cagrilintide 159 to 195 hours in another study, so about a week. Both fit one dose per week.84

Which side effects were seen with the components?

With both, mainly gastrointestinal effects such as nausea and diarrhoea, depending on the dose. On Retatrutide heart rate rose in a dose-dependent way in phase 2. Two satiety signals together may strengthen nausea at the start, this has not been measured for this blend.731

Which trials are still running?

Nine phase 3 trials of Retatrutide are running, the largest on heart and kidney events until 2029. The RENEW trials of cagrilintide alone run until 2027. No trial of the blend is listed in the registry.1213

Glossary

Terms explained briefly

Dotted words in the text open these explanations directly.

Agonist
A substance that binds to a receptor and activates it, like the body's own messenger. A triple agonist activates three different receptors.
Amylin
Hormone that the pancreas releases together with insulin. It slows gastric emptying and signals fullness to the brain.
GIP
Glucose-dependent insulinotropic polypeptide: a second gut hormone that boosts insulin release when blood sugar is high.
GLP-1
Glucagon-like peptide 1: gut hormone that releases insulin, slows gastric emptying and signals fullness in the brain.
Glucagon
Pancreatic hormone. It can raise blood sugar and increases fat breakdown and energy use in the liver.
Half-life
Time after which only half of a substance is left in the blood.
Incretins
Gut hormones such as GLP-1 and GIP that are released after eating and boost the insulin response.
Lyophilisate
Freeze-dried powder. Without water a peptide keeps much longer.
MASLD
Metabolic dysfunction-associated steatotic liver disease, the fatty liver formerly mostly called NAFLD.
Placebo
Dummy preparation without active substance. Comparing against it shows what is due to the substance itself.
Subcutaneous
Into the fat layer just under the skin.
Trial phases
Phase 1 tests tolerability in a few people, phase 2 looks for the dose, phase 3 confirms benefit and safety in thousands. After that, approval can be requested.

Dôkazy

Zdroje

Show all 15 sourcesHide sources 11 Studies2 Trial registry2 Database checked 26 Oct 2026

Studies

  1. Retatrutide: phase 2 study in obesity

    Jastreboff et al., New England Journal of Medicine, 2023

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  2. Retatrutide: phase 2a substudy on liver fat (MASLD)

    Sanyal et al., Nature Medicine, 2024

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  3. Cagrilintide: phase 2 dose-finding trial

    Lau et al., The Lancet, 2021

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  4. Cagrilintide with semaglutide: phase 1b trial with half-life

    Enebo et al., The Lancet, 2021

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  5. Cagrilintide with semaglutide: phase 3 trial REDEFINE 1

    Garvey et al., New England Journal of Medicine, 2025

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  6. Retatrutide: phase 3 trial TRIUMPH-1 in obesity

    Jastreboff et al., New England Journal of Medicine, 2026

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  7. Retatrutide: phase 3 trial TRIUMPH-2 with type 2 diabetes

    Bellido et al., The Lancet, 2026

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  8. Retatrutide: phase 1b study with half-life

    Urva et al., The Lancet, 2022

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  9. Retatrutide: discovery and pharmacology of the triple agonist

    Coskun et al., Cell Metabolism, 2022

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  10. Cagrilintide: binding to amylin and calcitonin receptors

    Cao et al., Nature Communications, 2025

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  11. Review of amylin and amylin analogues

    Alhazmi et al., Diabetes, Obesity and Metabolism, 2026

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed

Trial registry

  1. Trials of the components on ClinicalTrials.gov

    ClinicalTrials.gov, U.S. National Library of Medicine

    Checked 26 Oct 2026 via ClinicalTrials.gov API v2
  2. Search for Retatrutide and cagrilintide together (no trial)

    ClinicalTrials.gov, U.S. National Library of Medicine

    Checked 26 Oct 2026 via ClinicalTrials.gov API v2

Database

  1. Retatrutide: mechanism and targets in ChEMBL

    ChEMBL, EMBL-EBI (CHEMBL5095485)

    Checked 26 Oct 2026 via ChEMBL
  2. Cagrilintide: development phase in ChEMBL

    ChEMBL, EMBL-EBI (CHEMBL4802169)

    Checked 26 Oct 2026 via ChEMBL

V obchode

Reta + Cagri Blend in the catalog

Veľkosti, ceny a časy odoslania nájdete na stránke produktu.

K produktu